Our History

  • 2018February

    Listed on the KOSDAQ Stock Market

  • 2017December

    Awarded Orphan Drug Designation by US FDA on ARS

    September

    Awarded AA from Technology Evaluation

    July

    CRIOM Phase II IND US FDA Approval

    May

    Presented to American Association of Immunologists (AAI) (Including improvement of disease with EC-18 through regulation of neutrophil migration in pneumonia model)

    Approvd for Phase II Clinical Development by US FDA

  • 2016December

    Phase 2 clinical trials approved by Korean Ministry of Food and Drug Safety (CIN)

    CIN Phase II IND Korea MFDS Approval

    November

    Awarded 3rd KDDF Government Grant for Global New Drug Development

    July

    Successful Compliance with US FDA Regulation for US Export

    CIN Phase II IND US FDA Approval

    May

    Presented to the International Conference of the Korean Society of Biochemistry and Molecular Biology (KSBMB) (including improvement of disease of EC-18 through control of neutrophil migration in the rheumatoid arthritis model)

    Presented to the Annual Meeting of the American Association of Immunologists (AAI) (Including improvement of disease with EC-18 through regulation of neutrophil migration in acute lung Injury)

  • 2015October

    Awarded 2nd KDDF Government Grant for Global New Drug Development

    May

    IND (Investigational New Drug) approved by US FDA

    March

    GMP qualification granted to Seoul Cepha Plant by Japan PMDA (FDA)

    February

    Awarded 1st KDDF Government Grant for Global New Drug Development

    January

    Pharm Navi Selected by KFDA

    Selected by the Korea Ministry of trade, industry and energy as a new technology product

  • 2014September

    CIN Investigators initiated study at Asan Medical Center

    June

    EC-18 Approved Investigational New Drug by K-FDA

  • 2013January

    Seoul Plant 2 Certified for GMP by Korean Ministry of Food and Drug Safety

    Seoul Plant 2 Certified for GMP by K-FDA

    1st Human Clinical Trial for EC-18 Conducted by Myung-Ji Hospital of Kwandong University

    September

    Listed on the KONEX Stock Market

  • 2011June

    Acquired New Health Technology Certification from the Korea Health Industry Development Institute (KHIDI)

    March

    Selected as a Columbus Project Company by the Ministry of Health & Welfare

    February

    Successful Commercial Production of EC-18

  • 2009April

    Completed plant inspection by Otto Brands GmbH, Hamburg, Germany for D-Cycloserine Production

  • 2008April

    Seoul Plant 1 Certified for GMP by Korean Ministry of Food and Drug Safety

  • 2007March

    INNOBIZ certification awarded by Small & Medium Business Administration

  • 2004November

    Awarded the “Tower of Million-Dollar Export” by Ministry of Commerce, Industry & Energy

  • 2000March

    Acquired the Korea Good Technology Mark (KT) (Dept.of Education, Science & Technology)

  • 1999July

    Enzychem Lifesciences is founded